Replies to post #188137 on Biotech Values

[DewDiligence]

FDA approves TSRO’s Varubi (rolapitant) for prevention of chemo-induced nausea:

http://finance.yahoo.com/news/tesaro-announces-u-fda-approval-120100051.html

TSRO is up only 2% today, so this approval must have been widely expected. TSRO licensed the commercial rights to Varubi in most of the world from OPK in 2010.